Documentation

Press release

Datesort ascending Press release
02/05/2018 Information relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2018 (in french only)
16/04/2018 Publication of the 2017 registration document (only in French)
03/04/2018 Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
28/03/2018 Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
13/03/2018 Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society
08/03/2018 Inventiva to present at six investor conferences in March 2018
07/03/2018 2017 Full Year Results: Major progress achieved in clinical development and strong cash position
26/02/2018 Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients
12/02/2018 Inventiva Full-Year 2017 Financial Information and Business Update
01/02/2018 Half-yearly review and termination of a liquidity contract with Oddo BHF. Implementation of a new liquidity contract with Kepler Cheuvreux
31/01/2018 Inventiva to present in vivo data with odiparcil at the 14th WORLDSymposium™
04/01/2018 Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor
03/01/2018 Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI
13/11/2017 Inventiva to Present at Two Upcoming Investor Conferences
17/10/2017 Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment
26/09/2017 INVENTIVA: FIRST-HALF 2017 RESULTS
18/09/2017 Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)
05/09/2017 Inventiva announces exercise of option by Boehringer Ingelheim to jointly develop potential new treatments for idiopathic pulmonary fibrosis (IPF)
04/09/2017 Inventiva and AbbVie Extend Agreement to Discover New Potent Orally-Available Small Molecule RORγ Inverse Agonist Drug Candidates
29/08/2017 Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency

Pages